Continuing Education Activity

Thalidomide is a medication used to manage and treat advanced leprosy and multiple myeloma, and various other solid and hematologic malignancies. It is in the immunomodulatory class of medications. This activity reviews the indication, action, and contraindications for thalidomide as a valuable agent in the treatment of leprosy, multiple myeloma, and other malignancies when applicable. This activity will highlight the mechanism of action, adverse event profile, and other key factors pertinent for interprofessional team members managing the care of patients with leprosy, multiple myeloma, and other malignancies and their related conditions.

Objectives:

• Describe the unique molecular composition of thalidomide and how this affects the drug’s therapeutic and adverse effects.
• Identify the most common adverse effects associated with thalidomide therapy.
• Summarize proper treatment and responses to thalidomide toxicity.
• Explain the importance of the interprofessional healthcare team monitoring patients taking thalidomide, especially females of reproductive age.

Indications

Historically, thalidomide is best known for its introduction during the 1950s as a sedative and antiemetic marketed to women to treat pregnancy-related morning sickness.[1] During this time, the compound quickly developed its infamous reputation as one of the most potent teratogenic substances ever promoted, as approximately 10,000 children were born with profound limb and internal organ abnormalities, later referred to as the "children of thalidomide." The compound was then banned until later research demonstrated novel applications to its poorly understood mechanism of action. In the 1990s, the drug was repurposed, as the FDA approved it to treat conditions such as erythema nodosum leprosum. This repurposing generated further research into understanding the drug's mechanisms and ultimately uncovered its effective anti-inflammatory, immunomodulatory and anti-angiogenic activities.[2] Such properties have led to further FDA approval for the treatment of multiple myeloma.[3] Thalidomide also has an orphan designation for the treatment for the following:

•  Graft versus host disease
•  Mycobacterial infection
•  Severe recurrent aphthous stomatitis
•  Primary brain malignancies
•  HIV- associated wasting syndrome
•  Crohn disease
•  Kaposi sarcoma
•  Myelodysplastic syndrome
•  Hematopoietic stem cell transplantation
•  Hereditary hemorrhagic telangiectasia.[2][4][5][6]

Mechanism of Action

Thalidomide is a racemic glutamic acid analog with interchanging S(-) and R(+) enantiomers.[1] The S(-) enantiomer directly inhibits the release of TNF-alpha, while the R(+) enantiomer acts as a sedative via sleep receptors. Spontaneous hydrolysis of thalidomide at physiologic PH results in the generation of approximately 20 different compounds. Metabolic enzymes act on these compounds to generate other active metabolites, which result in the inhibition of angiogenesis and endothelial cell proliferation.[7][8]

Administration

Dosing of thalidomide is usually via the oral route with various strengths up to 200 mg tablets for all known treatment indications.[1][9] However, some sources question the bioavailability of thalidomide after oral administration due to its spontaneous hydrolysis and incomplete absorption.[10][11][9] Studies of intravenous administration demonstrate similar bioavailability to that of oral, while studies of other dosage forms could not be found.[9] Thus, the development of novel drug delivery systems in the form of biodegradable thalidomide implants has been a topic of research.[10]

Adverse Effects

Thalidomide treatment may be limited by its many adverse effects caused by numerous active metabolites derived from the degradation of its enantiomers.[1] Common side effects include constipation, hypothyroidism, ACTH stimulation, hypoglycemia, xerostomia, fever, mood changes, headache, peripheral neuropathy, somnolence, sedation, rash, and deep vein thrombosis.[10][12][13][14]

Contraindications

The use of thalidomide correlates with significant contraindications that physicians should consider before prescribing this compound. In particular, the FDA Black Box Warning involves embryo-fetal toxicity.[14] If administered to a pregnant patient, thalidomide can cause severe congenital defects or death. Thus, clinicians must avoid using thalidomide in pregnant women or women who may become pregnant while taking the drug. Before initiating treatment with any amount of this drug, pregnancy must be excluded with two negative pregnancy tests and subsequently prevented with two reliable contraceptive methods. Prescribers of thalidomide must also receive certification with the THALOMID REMS program through enrollment and compliance with the REMS requirements.[15]

A history of or significant risks to venous thromboembolic events represents another contraindication to the use of thalidomide therapy. Specifically, thalidomide increases the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients receiving treatment for multiple myeloma. This risk increases when using thalidomide in conjunction with chemotherapeutic agents such as dexamethasone.[16][17] Because of this effect, patients treated with thalidomide therapy may also benefit from prophylactic anticoagulation or aspirin treatment.[18] 

Previous hypersensitivity reactions represent the final contraindication to thalidomide usage. Patients who previously displayed severe adverse events such as Stevens-Johnson syndrome or type 1 hypersensitivity reaction to this drug should no longer be considered candidates for therapy.[19] 

Monitoring

Proper monitoring of patients treated with thalidomide is essential to ensuring a safe and efficacious treatment, as this drug is related to numerous, potentially severe, adverse events and reactions.[1] Despite questionable bioavailability via gastrointestinal absorption, almost all thalidomide therapy is delivered PO at dosages of 50-200 mg once daily.[10][20] Thalidomide is absorbed slowly, with peak concentrations occurring within 2 to 5 hours after ingestion.[20] Due to spontaneous hydrolysis at physiologic pH, >90% of thalidomide is renally excreted, with <5% of the drug being unchanged. The half-life of thalidomide is 5 to 7 hours, and toxicities may develop with increased dosage and duration of therapy.[20][14] The most common symptoms related to thalidomide toxicity include constipation, sedation, fatigue, and neuropathy.[14] 

Monitoring of patients treated with thalidomide involves routine healthcare visits to the prescribing physicians. Clinicians may check patients for developing neuropathy via complete neurological exams or EMG studies every six months. Lab work monitoring is also necessary for the elevation of liver enzymes and thyroid function. Patients treated with thalidomide and dexamethasone should be observed for signs and symptoms of thromboembolism and instructed to seek medical care if they develop shortness of breath, chest pain, or arm or leg swelling. The patient should report any adverse reactions to the clinician (including increased somnolence, constipation, etc.). Lastly, both physician and patient should be enrolled in the STEPS program to ensure proper monitoring of compliance and adverse reactions (described further in the “toxicity” section).[14][21]

Toxicity

There is no indicated antidote for thalidomide overdose. Thalidomide toxicity directly correlates with drug dosage and duration of therapy.[14] Patients taking 200 mg or less appear to have good therapeutic outcomes without evident toxicity, while dosages exceeding 400 mg/day almost always lead to toxicity-related symptoms. The most common symptoms related to thalidomide toxicity include constipation, sedation, fatigue, and neuropathy. Therapy exceeding six months is associated with an increase in neuropathy and hypothyroidism related to thalidomide toxicity. However, the incidence of constipation and sedation seems to decrease with the continued duration of therapy. Thalidomide toxicity also seems to increase when used in conjunction with dexamethasone or other chemotherapy drugs. Of those receiving thalidomide and dexamethasone for multiple myeloma treatment, approximately 10% will discontinue the treatment due to toxicity-related effects.[14][22][23]

Steps for addressing symptoms of thalidomide-related toxicity are listed below. 

•  Birth Defects 

  • All female patients with childbearing potential should receive two methods of contraception.
  • All male patients should abstain from intercourse or use a condom - even those with a vasectomy.
  • Both physician and patient should register for the S.T.E.P.S. program
• Peripheral neuropathy

  • Mild: Decrease the thalidomide dose by 50%
  • Moderate: Withhold thalidomide therapy until there is a resolution of toxicity and then restart at a 50% reduction
  • Severe: Discontinue thalidomide therapy
• Somnolence

  • Instruct patients to administer their total daily dose before going to bed
  • Patients should avoid driving or operating machinery
  • In cases of stupor or coma, suspend thalidomide therapy until toxicity resolves, then restart treatment at a 50% dose
• Constipation

  • Advise alteration of diet and exercise
  • Start the patient on a low-dose stool softener or laxative
  • In severe cases, withhold therapy until the condition resolves, then restart thalidomide with the addition of prophylactic laxative therapy and/or a 50% reduction in dose
• Skin rash

  • Mild to moderate skin rash: withhold thalidomide until there is a resolution of the toxicity and then resume treatment at a 50% reduction in dosage
  • Stevens-Johnson syndrome: discontinue therapy with no attempt to restart
• Orthostatic Hypotension 

  • The patient should sit upright for a few minutes before standing up from a recumbent position.
• All other toxicities

  • Withhold thalidomide until toxicity resolves to baseline, then restart at a 50% reduction in drug dosage
  • For all severe and life-threatening complications, discontinue thalidomide indefinitely.[14]

Further steps for addressing thalidomide toxicity involve enrolling both physician and patient into the System for Thalidomide Education and Prescribing Safety (S.T.E.P.S) program.[14][21] This program seeks to reduce misuse of thalidomide and thus mitigate adverse events (especially teratogenicity) via a three-pronged approach involving: access control, education of healthcare providers, pharmacists, and patients, and monitoring of compliance. 

Enhancing Healthcare Team Outcomes

Management of therapeutic drugs with the potential for extreme adverse effects requires an interprofessional team, including clinicians, pharmacists, nurses, and social workers. Likewise, the management of toxicities involved with such drugs requires various other healthcare providers, including clinicians, pharmacists, nurses, and laboratory technicians. Studies demonstrate improved treatment outcomes and healthcare costs when therapy incorporates such interprofessional teams.[24][25] [Level 1, Level 2]

The most common adverse effects of thalidomide therapy include constipation, sedation, fatigue, and neuropathy.[14] Such effects are related to therapeutic dosage and duration and can affect patient compliance and therapeutic benefits. More serious effects include increased thrombus formation and hypersensitivity reactions. To avoid missed indications of toxicity, healthcare providers at all levels must monitor any related symptoms and advise appropriate alterations to therapy – especially when therapy involves combined treatment with dexamethasone.[22] [Level 1]

Moreover, thalidomide is associated with extreme teratogenicity. As such, patients must enroll in the STEPS program, which involves a multidisciplinary team incorporating various healthcare specialists and social workers.[21] [Level 4] This program allows for proper patient education and monitoring of patient safety and compliance.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet. 2004 May 29;363(9423):1802-11. [PubMed: 15172781]

2.

Wu KL, Sonneveld P. [Thalidomide: new uses for an old drug]. Ned Tijdschr Geneeskd. 2002 Aug 03;146(31):1438-41. [PubMed: 12190008]

3.

Annas GJ, Elias S. Thalidomide and the Titanic: reconstructing the technology tragedies of the twentieth century. Am J Public Health. 1999 Jan;89(1):98-101. [PMC free article: PMC1508516] [PubMed: 9987477]

4.

Tuinmann G, Hegewisch-Becker S, Hossfeld DK. [New indications for thalidomide?]. Dtsch Med Wochenschr. 2001 Oct 19;126(42):1178-82. [PubMed: 11607859]

5.

Kumar S, Witzig TE, Rajkumar SV. Thalidomid: current role in the treatment of non-plasma cell malignancies. J Clin Oncol. 2004 Jun 15;22(12):2477-88. [PubMed: 15197211]

6.

Pałgan K, Pałgan I. [Thalidomide--new prospective therapy in oncology]. Wiad Lek. 2003;56(9-10):455-9. [PubMed: 15049211]

7.

Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today. 2015 Jun;105(2):140-56. [PMC free article: PMC4737249] [PubMed: 26043938]

8.

Vargesson N. The teratogenic effects of thalidomide on limbs. J Hand Surg Eur Vol. 2019 Jan;44(1):88-95. [PubMed: 30335598]

9.

Teo SK, Colburn WA, Tracewell WG, Kook KA, Stirling DI, Jaworsky MS, Scheffler MA, Thomas SD, Laskin OL. Clinical pharmacokinetics of thalidomide. Clin Pharmacokinet. 2004;43(5):311-27. [PubMed: 15080764]

10.

Pereira BG, Batista LF, de Souza PA, da Silva GR, Andrade SP, Serakides R, da Nova Mussel W, Silva-Cunha A, Fialho SL. Development of thalidomide-loaded biodegradable devices and evaluation of the effect on inhibition of inflammation and angiogenesis after subcutaneous application. Biomed Pharmacother. 2015 Apr;71:21-8. [PubMed: 25960210]

11.

Eriksson T, Björkman S, Roth B, Höglund P. Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. J Pharm Pharmacol. 2000 Jul;52(7):807-17. [PubMed: 10933131]

12.

Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J. 2005 Mar 22;7(1):E14-9. [PMC free article: PMC2751493] [PubMed: 16146335]

13.

Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol. 1996 Dec;35(6):969-79. [PubMed: 8959957]

14.

Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol. 2003 Sep-Oct;1(3):194-205. [PMC free article: PMC3134146] [PubMed: 15334875]

15.

Brandenburg NA, Bwire R, Freeman J, Houn F, Sheehan P, Zeldis JB. Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention. Drug Saf. 2017 Apr;40(4):333-341. [PMC free article: PMC5362654] [PubMed: 28074423]

16.

Kekre N, Connors JM. Venous thromboembolism incidence in hematologic malignancies. Blood Rev. 2019 Jan;33:24-32. [PubMed: 30262170]

17.

Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P., IFM 2009 Study. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017 Apr 06;376(14):1311-1320. [PMC free article: PMC6201242] [PubMed: 28379796]

18.

Storrar NPF, Mathur A, Johnson PRE, Roddie PH. Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens. Br J Haematol. 2019 Apr;185(1):142-144. [PubMed: 29785771]

19.

Schneider JA, Cohen PR. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures. Adv Ther. 2017 Jun;34(6):1235-1244. [PMC free article: PMC5487863] [PubMed: 28439852]

20.

Stansfield LC, Gonsalves WI, Buadi FK. The use of novel agents in multiple myeloma patients with hepatic impairment. Future Oncol. 2015;11(3):501-10. [PMC free article: PMC4361819] [PubMed: 25675129]

21.

Zeldis JB, Williams BA, Thomas SD, Elsayed ME. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther. 1999 Feb;21(2):319-30. [PubMed: 10211535]

22.

Rajkumar SV. Thalidomide in multiple myeloma. Oncology (Williston Park). 2000 Dec;14(12 Suppl 13):11-6. [PubMed: 11204667]

23.

Singhal S, Mehta J. Thalidomide in cancer: potential uses and limitations. BioDrugs. 2001;15(3):163-72. [PubMed: 11437682]

24.

Reeves S, Pelone F, Harrison R, Goldman J, Zwarenstein M. Interprofessional collaboration to improve professional practice and healthcare outcomes. Cochrane Database Syst Rev. 2017 Jun 22;6(6):CD000072. [PMC free article: PMC6481564] [PubMed: 28639262]

25.

O'Leary KJ, Johnson JK, Manojlovich M, Goldstein JD, Lee J, Williams MV. Redesigning systems to improve teamwork and quality for hospitalized patients (RESET): study protocol evaluating the effect of mentored implementation to redesign clinical microsystems. BMC Health Serv Res. 2019 May 08;19(1):293. [PMC free article: PMC6505207] [PubMed: 31068161]

Disclosure: Dayton Grogan declares no relevant financial relationships with ineligible companies.

Disclosure: Nicole Winston declares no relevant financial relationships with ineligible companies.